Mana.bio Strengthens Leadership Team and Prepares to Present AI-Driven LNP Data at ASGCT 2026
核心洞察
Mana.bio (搜索) appointed three strategic leaders including Thaminda Ramanayake as board member, bringing over 20 years of biopharmaceutical experience from CureVac and other major companies.
The company will present breakthrough data at ASGCT 2026 demonstrating machine learning-driven lipid nanoparticle design for in vivo T-cell (搜索) engineering applications.
Lead LNP candidates showed successful in vivo T-cell (搜索) delivery in non-human primates and achieved near complete B-cell tumor (搜索) clearance in mouse models.
Mana.bio (搜索), a biotechnology company developing AI-enabled lipid nanoparticle (LNP) discovery platforms, announced significant leadership additions and upcoming data presentation that highlight the company's progress in advancing targeted RNA delivery technologies. The strategic appointments bring deep expertise in mRNA therapeutics and business development as the company prepares to showcase breakthrough data on machine learning-driven LNP design.
Strategic Leadership Expansion
The company appointed Thaminda Ramanayake as a board member, Michelle Lynn-Hall as board observer, and Guy Van Meter as strategic advisor. Ramanayake brings over 20 years of global biopharmaceutical leadership experience, most recently serving as chief business officer at CureVac where he played a key role in the company's transformation and acquisition by BioNTech. His background includes senior roles at Sanofi, BioMarin Pharmaceuticals (搜索), and Amgen, with particular expertise in gene therapy and oligonucleotide-based assets.
Dr. Michelle Lynn Hall, co-founder and general partner of Entrée Bioventures, previously established and led Eli Lilly's Genetic Medicine division in Boston and led molecular modeling teams at Moderna focused on designing mRNAs, proteins, and LNPs. Guy Van Meter serves as chief business officer at Adimab (搜索), where he has helped build the company into a premier antibody discovery platform with more than 140 partners and over 650 therapeutic programs.
"We are at a transformational moment at Mana.bio (搜索)," stated Yogev Debbi, co-founder and CEO. "While the field is just realizing the potential of AI-driven drug discovery, Mana.bio has already built an industry-leading platform with established robust proof-of-concept."
Breakthrough Data on AI-Driven LNP Design
Mana.bio (搜索) will present new data at the ASGCT 2026 Annual Meeting in Boston, demonstrating how machine learning models trained on the world's largest LNP dataset identified multiple proprietary passive-targeted LNP formulations. The research, titled "Machine Learning-Driven Design of Lipid Nanoparticles for In Vivo T-Cell (搜索) Engineering," showcases the platform's ability to predict T-cell transfection efficiency, chimeric antigen receptor (CAR (搜索)) function, in vivo safety, and physicochemical stability.
The lead candidates demonstrated successful in vivo delivery to T-cells in non-human primates after a single dose of fluorescent reporter. More significantly, the therapeutic constructs achieved near complete B-cell tumor (搜索) clearance in mice after multiple doses of a therapeutic CAR (搜索) construct, highlighting the potential for in vivo T-cell (搜索) engineering as an alternative to ex vivo cell therapies.
Platform Technology and Applications
Mana.bio (搜索)'s AI/ML platform has generated multiple extrahepatic delivery solutions with non-human primate validation, enabling tissue-specific delivery of nucleic acid therapeutics across various organs and immune cell types. The company has also developed a predictive safety model designed to de-risk LNP design in early development, addressing a critical bottleneck in advancing RNA therapeutics.
The presentation underscores the company's vision of enabling in vivo T-cell (搜索) engineering as a streamlined, scalable alternative to ex vivo cell therapies, with potential to broaden patient access to next-generation genetic medicines. The technology platform represents a significant advancement in addressing the delivery challenges that have limited the broader application of RNA-based therapeutics beyond liver-targeted applications.
Founded in Tel Aviv, Israel, Mana.bio (搜索) is backed by Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, Entree Bio and the Technion – Israel Institute of Technology. The company's focus on AI-driven LNP optimization positions it at the forefront of efforts to expand the therapeutic potential of RNA medicines through improved delivery systems.